Open tender · Germany · Pharmaceutical products
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Lamivudin + Abacavir + Dolutegravir, ATC J05AR13 für die Zeit 01.07.2025 - 30.06.2027
In EnglishConclusion of a non-exclusive discount agreement under § 130a para. 8 SGB V for the active ingredient Lamivudine + Abacavir + Dolutegravir, ATC J05AR13 for the period 01.07.2025 - 30.06.2027
DAK-Gesundheit in Germany is inviting bids for “Conclusion of a non-exclusive discount agreement under § 130a para. 8 SGB V for the active ingredient Lamivudine + Abacavir + Dolutegravir, ATC…”. Bids close on 5 May 2027, 12:00 CEST. askTender lists every requirement to qualify and checks whether your company meets them.
Key facts
- Procedure
- Contract notice
Before you bid, askTender
Everything else is in your askTender account
The requirements to qualify, the eligibility check and the bid documents for this tender are in your askTender account.
- What it takes to qualify: every requirement, in the tender’s own words
- Whether your company qualifies: your profile checked against each requirement, showing what you have, what’s missing and how to close the gap
- The documents to file: a checklist, with draft declarations ready to sign
- A bid partner for any requirement you can’t meet alone
- The tender documents, ready to open
- Alerts for new tenders like this one
Public data: TED – Tenders Electronic Daily. © European Union, 1998–2026. Notices reused under Commission Decision 2011/833/EU. · Sources & licences